311 related articles for article (PubMed ID: 19358143)
21. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
[TBL] [Abstract][Full Text] [Related]
22. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
24. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
27. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
29. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
30. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
[TBL] [Abstract][Full Text] [Related]
31. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
[TBL] [Abstract][Full Text] [Related]
32. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
[TBL] [Abstract][Full Text] [Related]
33. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
[TBL] [Abstract][Full Text] [Related]
34. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
35. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
36. [Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma].
Zhang Q; Zhang HY; Zhong FL; Zhang WL; Xu L; Feng J; Meng QX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):399-402. PubMed ID: 23628041
[TBL] [Abstract][Full Text] [Related]
37. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
38. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
[TBL] [Abstract][Full Text] [Related]
39. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
